Programmed CD34+ cell therapy - Fate Therapeutics

Drug Profile

Programmed CD34+ cell therapy - Fate Therapeutics

Alternative Names: PD-L1 CD34+ cell therapy - Fate Therapeutics; ToleraCyteTM

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fate Therapeutics
  • Developer Boston Childrens Hospital; Fate Therapeutics
  • Class Anti-inflammatories; Antihyperglycaemics; Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 01 Nov 2017 The US Patent and Trademark Office issues patent covering the use of prostaglandins as viral transduction enhancers for the genetic modification of CD34+ haematopoietic cells
  • 03 Mar 2016 Preclinical trials in Autoimmune disorders in USA (Parenteral)
  • 03 Mar 2016 Fate Therapeutics and Boston Children's Hospital enter into a collaboration to develop programmed CD34+ cell therapy (Fate Therapeutics, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top